论文部分内容阅读
日本国三重大学小儿科近期约五年半期间,对过氧化酶阴性,a—NFA,NFA阴性、TdT阳性,形态学也表现为急性淋巴性白血病,免疫学诊断为ALL的264例中的40例(15.1%)表面抗原分析中发现除ALL特征外同时表现有髓系统抗原(CD11b,CD11c,CD13,CD14,CD15,CD16,CD33,CD36)仅表现一种髓系统抗原的24例,2种的6例,3种9例,5种抗原同时表现的1例。施行染色体分析的22例中正常核型仅2例其它均呈现了多种类型的染色体异常。进行了临床资料,免疫学的分析。预后方面有双标记(淋巴系髓系抗原同时表现)的病例尽管原来划归标危型ALL组也呈现了高再发率的不良结果,因此我们认为双标记的出现可以作为危险因子中的一个因子来选择更合适的化疗也许是必要的。
Pediatrics in Japan’s Mie University recently about five and a half period, the peroxidase-negative, a-NFA, NFA-negative, TdT-positive, morphology also showed acute lymphoblastic leukemia, immunologically diagnosed ALL of 264 cases of 40 (15.1%) in the analysis of surface antigens showed that in addition to the ALL characteristics, 24 cases of myeloid antigens were found in both the myeloid antigens (CD11b, CD11c, CD13, CD14, CD15, CD16, CD33, CD36) 6 cases, 3 kinds of 9 cases, 5 kinds of antigens in 1 case at the same time. Among the 22 cases with normal karyotype, only 2 cases showed other types of chromosomal abnormalities. The clinical data, immunological analysis. Prognosis with dual markers (lymphatic myeloid antigens simultaneously) cases Despite the original assigned to the standard risk ALL group also showed a high recurrence rate of adverse outcomes, so we think double labeling can be used as one of the risk factors Factors to choose a more appropriate chemotherapy may be necessary.